Anticholinergic burden in the German National Cohort (NAKO): patterns of anticholinergic drug exposure and utilization
Autor/innen
- Julie K. Könnecke
- Nele L. Bößneck
- Alexandra Drebka
- Annika J. Scholl
- Miriam Degen
- Nina Ebert
- Margit Heier
- Thomas Keil
- Michael Leitzmann
- Rafael Mikolajczyk
- Ilais Moreno Velásquez
- Nadia Obi
- Phil Pendt
- Tobias Pischon
- Nahlah Sallam
- Ben Schöttker
- Margarethe Woeckel
- Beatrice E. Bachmeier
Journal
- Exploratory Research in Clinical and Social Pharmacy
Quellenangabe
- Explor Res Clin Soc Pharm 24: 100869
Zusammenfassung
BACKGROUND: Medication-related anticholinergic burden (AB) has been studied mainly in older adults and selected patient populations, whereas population-based evidence across adulthood remains limited, particularly regarding over-the-counter (OTC) drug use and utilization patterns.
OBJECTIVE: To characterize the frequency, distribution, and pharmacological drivers of AB in the German National Cohort (NAKO).
METHODS: We conducted a cross-sectional analysis of NAKO baseline data collected in 2014–2019 from participants aged 19–75 years recruited through age- and sex-stratified random sampling from population registries. AB was quantified from participant-reported seven-day medication use using the German Anticholinergic Burden Scale; cumulative scores ≥ 1 and ≥ 3 defined any and high burden, respectively. Descriptive analyses characterized AB by age, sex, drug class, prescription status, and utilization pattern; logistic regression assessed associations of AB with age, sex, and polypharmacy.
RESULTS: Among 199,813 participants (median age 51 years; 50.4% women), 17.4% had any and 3.0% had high AB, with exposure in all analyzed age groups. Any and high AB were associated with female sex (aOR = 1.09, 95% CI 1.06–1.12 and aOR = 1.44, 95% CI 1.37–1.53, respectively), most older age groups, and polypharmacy. Nervous system drugs contributed most to aggregate AB. Medications obtained OTC accounted for over one tenth of the sample's burden, with a greater relative contribution in younger age groups. Most anticholinergic drugs were used on a scheduled basis, with daily and long-term use predominating.
CONCLUSION: In this large population-based cohort, anticholinergic exposure was observed across all examined age groups, and OTC medications made a non-negligible contribution to the overall burden. These findings suggest that age range and non-prescription medication use may be important considerations when assessing AB.